There was evidence that changes in SGRQ domain and total scores could detect within-subject improvement in health status, and differentiate groups of patients whose health status had improved, declined or remained unchanged.
However, the within-subject improvement in INRs as well as the improvements in adherence both among subjects in whom we had MEMS cap adherence data pre-intervention and compared to historical controls were quite large.
In addition, within-subject improvement in outcomes from baseline at 12, 24, 36 and 48 months will be analysed by paired t-test for continuous outcomes and McNemar test for binary outcomes.
Other estimated treatment assignment effects were not significant different although there was an extensive within-subject improvement on the primary outcome RDQ (about 10 points improvement on the RDQ from baseline to one year after delivery) in both study groups and on several secondary outcomes (Tables 1, 2).
Noteworthy, in a proof-of-concept clinical trial with 39 patients carrying the G551D mutation, Ivacaftor administered orally exhibited a within-subject improvement in CFTR markers and lung function, suggesting that potentiators may be a viable therapeutic approach for the treatment of at least some CF patients (Accurso et al, 2010).
(c) Only one subject reported a subjective improvement due to treatment.
The number of subjects displaying a subjective improvement in motion sickness was compared against the true value (i.e. 8 of 15 subjects with improvement) that would be expected if no rizatriptan treatment effect existed.
Where melatonin was used for CP patients with sleep problems/disorders, several related to phase or sleep maintenance disorders, improvements in sleep latency and night waking were consistently found, and in some subjects, improvements in total sleep time.
However, there were significant within-subject improvements in FEV1 from baseline with the 75 mg and 150 mg doses.
There were significant differences in BII at the End-of-Study Visit between subjects reporting improvement versus subjects reporting no improvement (Studies 1 and 2, P <.0001) and subjects taking tadalafil versus subjects taking placebo (Study 1, P =.0045; Study 2, P =.0064).
